These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 26122726)

  • 21. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
    J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LA-EP2006: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
    Takano T; Ito M; Kadoya T; Osako T; Aruga T; Masuda N; Miyaki T; Niikura N; Shimizu D; Yokoyama Y; Watanabe M; Tomomitsu M; Aogi K
    Cancer Med; 2023 Oct; 12(20):20242-20250. PubMed ID: 37824431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.
    Hegg R; Mattar A; Matos-Neto JN; Pedrini JL; Aleixo SB; Rocha RO; Cramer-Junior RP; van-Eyll-Rocha S
    Clinics (Sao Paulo); 2016 Oct; 71(10):586-592. PubMed ID: 27759847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
    Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
    Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
    Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
    Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
    Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®).
    Wong G; Zhang L; Majeed H; Razvi Y; DeAngelis C; Lam E; McKenzie E; Wang K; Pasetka M
    J Oncol Pharm Pract; 2022 Jan; 28(1):5-16. PubMed ID: 33215563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH; Sohn JH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Hong DS; Park S; Shin SH; Kwon HC; Seo JH
    Invest New Drugs; 2013 Oct; 31(5):1300-6. PubMed ID: 23677653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
    Aapro MS; Chaplin S; Cornes P; Howe S; Link H; Koptelova N; Mehl A; Di Palma M; Schroader BK; Terkola R
    Support Care Cancer; 2023 Sep; 31(10):581. PubMed ID: 37728795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
    Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
    Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
    Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
    Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
    BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
    Hoy SM
    BioDrugs; 2019 Feb; 33(1):117-120. PubMed ID: 30701419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
    Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
    BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
    Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
    J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.